E-Newsletter - October 2016

stereotactic radiosurgery may be best for patients with metastatic brain tumors

Patients with three or fewer metastatic brain tumors who received treatment with stereotactic radiosurgery (SRS) had less cognitive deterioration three months after treatment than patients who received SRS combined with whole brain radiation therapy (WBRT). These findings are according to the results of an Alliance trial - NCCTG N107C A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease - published recently in the Journal of the American Medical Association.

"Metastatic brain tumors are unfortunately common in patients with cancer," said Paul Brown, MD, a radiation oncologist at Mayo Clinic and study chair. Dr. Brown said that, while SRS gives physicians the opportunity to treat tumors and spare healthy brain tissue, a combination of SRS plus WBRT has been shown to help control growth of metastatic brain tumors. "The concern is that WBRT also damages cognitive function," he said. "That is why we have been studying the use of SRS alone."

Researchers enrolled 213 patients between February 2002 and December 2013, and randomly assigned them to treatment with SRS alone (111) or SRS followed by WBRT (102). Researchers found less cognitive deterioration at three months in patients treated with SRS alone. Quality of life (QOL) was also higher at three months among patients treated with SRS alone. There was no significant difference in functional independence at three months between treatment groups. Median overall survival was 10.4 months for patients treated with SRS alone and 7.4 months for patients treated with SRS and WBRT.

"This is the first large-scale clinical trial to evaluate this patient population with a comprehensive battery of cognitive and QOL instruments," Dr. Brown said. "WBRT has often been offered early in the disease course for patients with metastatic brain tumors, but, because of this trial, we know the negative impact of WBRT on both quality of life and cognitive function is significant. With these trial findings, we expect practice will shift, reserving WBRT for patients with more extensive disease in the brain."

The trial is currently ongoing, but not recruiting patients. To learn more about the trial, visit https://clinicaltrials.gov/ct2/show/NCT01372774.

For other articles in the October issue of the Alliance E-News newsletter, see below.